It was reported that trabectedin has dual effects on anticancer including inducing the differentiation and apoptosis of malignant cells and regulating the tumor microenvironment by limiting the associated inflammatory mediator production such as CCL2, interleukin-6, and VEGF (Poveda et al., 2014; Ventriglia et al., 2018). The gene discussed is CCL2; the disease is neoplasm.